Hanping Wang
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Lung Cancer Research Studies
Papers in
- Oncology 57
- Cancer Immunotherapy and Biomarkers 50
- Lung Cancer Research Studies 4
-
- Lung Cancer Treatments and Mutations 18
- Co-authors
- Li Zhang (40 shared papers)Xiaoyan Si (52 shared papers)Xiaotong Zhang (32 shared papers)Mengzhao Wang (30 shared papers)Lian Duan (18 shared papers)Xiaoxiao Guo (19 shared papers)Jiaxin Zhou (18 shared papers)Peng Song (7 shared papers)
- Journals
- Thoracic Cancer (31 papers)Lung Cancer (3 papers)Frontiers in Oncology (2 papers)BMC Medicine (2 papers)Journal for ImmunoTherapy of Cancer (2 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Hanping Wang
108 papers receiving 1.8k citations
Hanping Wang's Hit Papers
Peers
Comparison fields: 5 of 114
- Oncology 769
- General Dentistry 6
- Pulmonary and Respiratory Medicine 318
- Hepatology 50
- Periodontics 34
Countries citing papers authored by Hanping Wang
This map shows the geographic impact of Hanping Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanping Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanping Wang more than expected).
Fields of papers citing papers by Hanping Wang
This network shows the impact of papers produced by Hanping Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanping Wang. The network helps show where Hanping Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Hanping Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 116 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Risk of COVID-19 for patients with cancer Hit paper breakdown → | 2020 | 350 |
| 2 | 2019 | 78 | |
| 3 | 2020 | 75 | |
| 4 | 2021 | 64 | |
| 5 | 2024 | 60 | |
| 6 | 2019 | 55 | |
| 7 | 2021 | 50 | |
| 8 | 2022 | 48 | |
| 9 | Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. | 2011 | 36 |
| 10 | 2020 | 35 | |
| 11 | 2018 | 34 | |
| 12 | 2018 | 33 | |
| 13 | 2024 | 33 | |
| 14 | 2020 | 32 | |
| 15 | 2024 | 32 | |
| 16 | 2016 | 30 | |
| 17 | 2017 | 29 | |
| 18 | 2023 | 28 | |
| 19 | 2019 | 25 | |
| 20 | 2016 | 23 |
About Hanping Wang
Hanping Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Rheumatology, Ecology, Evolution, Behavior and Systematics and Cardiology and Cardiovascular Medicine, having authored 116 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (50 papers), Lung Cancer Treatments and Mutations (18 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers), Lung Cancer Research Studies (4 papers), Plant Ecology and Taxonomy Studies (4 papers), IgG4-Related and Inflammatory Diseases (4 papers), Plant Diversity and Evolution (4 papers) and Gut microbiota and health (4 papers). The work is most often cited by research in Oncology (769 citations), General Dentistry (6 citations), Pulmonary and Respiratory Medicine (318 citations), Hepatology (50 citations) and Periodontics (34 citations). Hanping Wang has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Li Zhang, Xiaoyan Si, Xiaotong Zhang, Mengzhao Wang, Lian Duan, Xiaoxiao Guo, Jiaxin Zhou, Peng Song, Haitao Zhao and Xiaoxia Cui. Their work appears in journals such as Thoracic Cancer, Lung Cancer, Frontiers in Oncology, BMC Medicine and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.